Scholarlink

Background <p>In Japan, multiagent chemotherapy comprising anthracycline and cytarabine is commonly used as post-remission consolidation therapy for acute myeloid leukemia. Meanwhile, intermediate-dose cytarabine (ID-AC) is typically utilized in Western countries. However, data comparing these two regimens are limited. The current study retrospectively analyzed the outcomes of multiagent chemotherapy and ID-AC as consolidation therapy in patients at our institution.</p> Methods <p>Seventy-one patients were included in the multiagent chemotherapy group and 46 in the ID-AC group.</p> Results <p>Two-year overall survival rates did not differ significantly between the multiagent chemotherapy and ID-AC groups (56.0% vs. 69.2%; P = 0.169). Similarly, 2-year disease-free survival with data censored at the time of allogeneic stem cell transplantation did not significantly differ between groups (14.1% vs. 33.5%; P = 0.268). The ID-AC group had a significantly lower incidence of febrile neutropenia than the multiagent chemotherapy group. Further, the ID-AC group had a significantly shorter duration of neutropenia and length of hospital stay than the multiagent chemotherapy group.</p> Conclusion <p>ID-AC had comparable efficacy and a more favorable safety profile than multiagent chemotherapy as consolidation therapy for acute myeloid leukemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Intermediate-dose cytarabine as a safer consolidation strategy for acute myeloid leukemia

  • 期刊论文

  • 发表日期：

    2025年12月26日

查看全文
  • Toshiyasu Sakai,
  • Kotaro Miyao,
  • Taito Kiwada,
  • Somi Ozaki,
  • Tomoyoshi Wakayama,
  • Masaya Numata,
  • Shuto Negishi,
  • Hitomi Sawa,
  • Yuichiro Inagaki,
  • Masashi Sawa

摘要

Background

In Japan, multiagent chemotherapy comprising anthracycline and cytarabine is commonly used as post-remission consolidation therapy for acute myeloid leukemia. Meanwhile, intermediate-dose cytarabine (ID-AC) is typically utilized in Western countries. However, data comparing these two regimens are limited. The current study retrospectively analyzed the outcomes of multiagent chemotherapy and ID-AC as consolidation therapy in patients at our institution.

Methods

Seventy-one patients were included in the multiagent chemotherapy group and 46 in the ID-AC group.

Results

Two-year overall survival rates did not differ significantly between the multiagent chemotherapy and ID-AC groups (56.0% vs. 69.2%; P = 0.169). Similarly, 2-year disease-free survival with data censored at the time of allogeneic stem cell transplantation did not significantly differ between groups (14.1% vs. 33.5%; P = 0.268). The ID-AC group had a significantly lower incidence of febrile neutropenia than the multiagent chemotherapy group. Further, the ID-AC group had a significantly shorter duration of neutropenia and length of hospital stay than the multiagent chemotherapy group.

Conclusion

ID-AC had comparable efficacy and a more favorable safety profile than multiagent chemotherapy as consolidation therapy for acute myeloid leukemia.